Vertex moves experimental cystic fibrosis drugs into PhIII
Vertex Pharmaceuticals has chosen to advance experimental therapies VX-659 and VX-445 into late stage development as part of two different triple combination regimens for people with cystic fibrosis (CF).
Read More





